Category: Alzheimer Disease
Shots: The approval is based on the two P-III clinical trials i.e EMERGE and ENGAGE along with P-Ib PRIME study involves assessing the efficacy of Aduhelm vs PBO in patients with early stages of AD with confirmed presence of amyloid pathology Results: the therapy consistently showed a dose and time-dependent effect on the reduction of […]
Shots: The company has completed the enrollment in the P-IIB HOPE4MCI trial evaluating the efficacy of AGB101 vs PBO in 164 patients to treat amnestic mild cognitive impairment due to AD across 23 sites in the US and Canada The HOPE4MCI study followed an earlier study that showed a reduction in hippocampal overactivity and improvement […]
Shots: The US FDA has granted FT Designation to LX1001 for the treatment of APOE4 associated AD. The designation evaluates to facilitate the development and expedite the review of drug The company has initiated P-I trial to assess the safety and toxicity of LX1001 as a potential one-time treatment for early-stage AD patients with mild […]
Shots: The P-IIb POC Study 201 involves assessing lecanemab in patients with early AD Results: @18mos, prespecified analysis showed a consistent reduction of clinical decline across several clinical and biomarker EPs at highest doses and reduction in brain Aβ & clinical decline. The results are published in a peer-reviewed journal In March, the companies have […]
Shots: Novo Nordisk plans to initiate a pivotal P-llla program to evaluate the efficacy and safety of Semaglutide (oral, 14mg, qd) vs PBO in 3,700 patients with AD with the anticipated initiation in H1’21 The decision follows the evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular […]
Shots: The submission is based on P-lll EMERGE and ENGAGE study assessing aducanumab vs PBO in patients with AD. The studies evaluate the efficacy of monthly doses of aducanumab in reducing cognitive and functional impairment The secondary objectives of the study were to assess the effect of monthly doses of aducanumab on the clinical decline […]
Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns PostEra […]